Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Angiolymphoid Hyperplasia With Eosinophilia Treatment & Management

  • Author: Sarah K Taylor, MD; Chief Editor: William D James, MD  more...
 
Updated: Jul 14, 2016
 

Approach Considerations

The most effective treatment for angiolymphoid hyperplasia with eosinophilia (ALHE) is generally surgical excision, but its success rate is limited. Pulsed dye laser and other destructive modalities are effective treatment options in select patients and topical medications have been reported to be successful.

Next

Medical Care

Treatment of angiolymphoid hyperplasia with eosinophilia (ALHE) is often challenging. Rarely, spontaneous resolution occurs, obviating the need for medical intervention in some cases. While surgery is considered the treatment of choice, management with intralesional corticosteroids may be a viable alternative in some cases, especially in cosmetically sensitive sites on the head and neck.[22] Irradiation has been used but is not optimal. A very promising treatment is oral propranolol, which has been used very successfully for infantile hemangiomas. One report noted no recurrence up to two years after oral propranolol therapy.[23] Topical timolol has also been shown to have some success.[24] Other local treatments that have been reported include topical imiquimod,[25] topical tacrolimus, and intralesional interferon alfa-2a.[26] Systemically, treatment with systemic corticosteroids, anti–interleukin 5 antibody (mepolizumab),[27] and isotretinoin[28] has also been reported.

Previous
Next

Surgical Care

Simple surgical excision is sometimes used, but the lesions tend to recur.[17] Mohs micrographic surgery has been attempted in order to address ALHE through better margin control. Excisions that include the arterial and venous segments at the base of the lesion prove most efficacious. The pulsed-dye laser[29] and carbon dioxide laser have been used with some success. 5-Aminolevulinic acid photodynamic therapy (ALA-PDT) has also been reported to show some success.[30] Cryosurgery[31] and electrosurgery have also been reported. More recently, intralesional radiofrequency ablation was also found to produce cosmetically pleasing and lasting results.[32]

Previous
 
Contributor Information and Disclosures
Author

Sarah K Taylor, MD Staff Physician, Eisenhower Army Medical Center Dermatology, Ft Gordon

Disclosure: Nothing to disclose.

Coauthor(s)

Earl J Glusac, MD Professor, Departments of Pathology and Dermatology, Yale University School of Medicine

Earl J Glusac, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Jon H Meyerle, MD Assistant Professor, Department Dermatology, Uniformed Services University of the Health Sciences; Assistant Professor, Department of Dermatology, Johns Hopkins University School of Medicine; Chief, Immunodermatology, Walter Reed National Military Medical Center

Jon H Meyerle, MD is a member of the following medical societies: American Academy of Dermatology, Sigma Xi

Disclosure: Nothing to disclose.

Specialty Editor Board

Michael J Wells, MD, FAAD Associate Professor, Department of Dermatology, Texas Tech University Health Sciences Center, Paul L Foster School of Medicine

Michael J Wells, MD, FAAD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, Texas Medical Association

Disclosure: Nothing to disclose.

Warren R Heymann, MD Head, Division of Dermatology, Professor, Department of Internal Medicine, Rutgers New Jersey Medical School

Warren R Heymann, MD is a member of the following medical societies: American Academy of Dermatology, American Society of Dermatopathology, Society for Investigative Dermatology

Disclosure: Nothing to disclose.

Chief Editor

William D James, MD Paul R Gross Professor of Dermatology, Vice-Chairman, Residency Program Director, Department of Dermatology, University of Pennsylvania School of Medicine

William D James, MD is a member of the following medical societies: American Academy of Dermatology, Society for Investigative Dermatology

Disclosure: Nothing to disclose.

Additional Contributors

Robert A Schwartz, MD, MPH Professor and Head of Dermatology, Professor of Pathology, Pediatrics, Medicine, and Preventive Medicine and Community Health, Rutgers New Jersey Medical School; Visiting Professor, Rutgers University School of Public Affairs and Administration

Robert A Schwartz, MD, MPH is a member of the following medical societies: Alpha Omega Alpha, New York Academy of Medicine, American Academy of Dermatology, American College of Physicians, Sigma Xi

Disclosure: Nothing to disclose.

Acknowledgements

Ashley R Mason, MD Dermatopathology Fellow, Department of Dermatology, Yale University School of Medicine

Ashley R Mason, MD is a member of the following medical societies: American Academy of Dermatology and International Society of Dermatopathology

Disclosure: Nothing to disclose.

References
  1. Hamilton TK, Baughman RD, Perry AE. Persistent pruritic plaque of the ear. Arch Dermatol. 1999 Apr. 135(4):464-5, 467-8. [Medline].

  2. Arnold M, Geilen CC, Coupland SE, Krengel S, Dippel E, Spröder J, et al. Unilateral angiolymphoid hyperplasia with eosinophilia involving the left arm and hand. J Cutan Pathol. 1999 Oct. 26(9):436-40. [Medline].

  3. Chen JF, Gao HW, Wu BY, Tsai WC, Chiang CP. Angiolymphoid hyperplasia with eosinophilia affecting the scrotum: a rare case report with molecular evidence of T-cell clonality. J Dermatol. 2010 Apr. 37(4):355-9. [Medline].

  4. Chan JK, Hui PK, Ng CS, Yuen NW, Kung IT, Gwi E. Epithelioid haemangioma (angiolymphoid hyperplasia with eosinophilia) and Kimura's disease in Chinese. Histopathology. 1989 Dec. 15(6):557-74. [Medline].

  5. Googe PB, Harris NL, Mihm MC Jr. Kimura's disease and angiolymphoid hyperplasia with eosinophilia: two distinct histopathological entities. J Cutan Pathol. 1987 Oct. 14(5):263-71. [Medline].

  6. Tsuboi H, Masuzawa M, Katsuoka K. Angiolymphoid hyperplasia with eosinophilia affecting the nail bed and underlying bone. J Dermatol. 2006 Jun. 33(6):399-402. [Medline].

  7. Esmaili DD, Chang EL, O'Hearn TM, Smith RE, Rao NA. Simultaneous presentation of Kimura disease and angiolymphoid hyperplasia with eosinophilia. Ophthal Plast Reconstr Surg. 2008 Jul-Aug. 24(4):310-1. [Medline].

  8. Zarrin-Khameh N, Spoden JE, Tran RM. Angiolymphoid hyperplasia with eosinophilia associated with pregnancy: a case report and review of the literature. Arch Pathol Lab Med. 2005 Sep. 129(9):1168-71. [Medline].

  9. Marcum CB, Zager JS, Bélongie IP, Messina JL, Fenske NA. Profound proliferating angiolymphoid hyperplasia with eosinophilia of pregnancy mimicking angiosarcoma. Cutis. 2011 Sep. 88(3):122-8. [Medline].

  10. Angiolymphoid Hyperplasia with Eosinophilia and Kimura Disease. Wolff, Goldsmith, Katz, Gilchrest, Paller, Leffell, eds. Fitzpatrick's Dermatology in General Medicine. 7th ed. New York, NY: McGraw-Hill Medical; 2008. Vol 1: 313-14.

  11. Joshi R. Angiolymphoid hyperplasia with follicular mucinosis. Indian J Dermatol Venereol Leprol. 2007 Sep-Oct. 73(5):346-7. [Medline].

  12. Kempf W, Haeffner AC, Zepter K, et al. Angiolymphoid hyperplasia with eosinophilia: evidence for a T-cell lymphoproliferative origin. Hum Pathol. 2002 Oct. 33(10):1023-9. [Medline].

  13. Andreae J, Galle C, Magdorf K, et al. Severe atherosclerosis of the aorta and development of peripheral T-cell lymphoma in an adolescent with angiolymphoid hyperplasia with eosinophilia. Br J Dermatol. 2005 May. 152(5):1033-8. [Medline].

  14. Gonzalez-Cuyar LF, Tavora F, Zhao XF, Wang G, Auerbach A, Aguilera N, et al. Angiolymphoid hyperplasia with eosinophilia developing in a patient with history of peripheral T-cell lymphoma: evidence for multicentric T-cell lymphoproliferative process. Diagn Pathol. 2008 May 29. 3:22. [Medline].

  15. Jeon EK, Cho AY, Kim MY, Lee Y, Seo YJ, Park JK, et al. Angiolymphoid hyperplasia with eosinophilia that was possibly induced by vaccination in a child. Ann Dermatol. 2009 Feb. 21(1):71-4. [Medline]. [Full Text].

  16. Korekawa A, Kaneko T, Hagiwara C, et al. Angiolymphoid hyperplasia with eosinophilia in infancy. J Dermatol. 2012 May 17. [Medline].

  17. Adler BL, Krausz AE, Minuti A, Silverberg JI, Lev-Tov H. Epidemiology and treatment of angiolymphoid hyperplasia with eosinophilia (ALHE): A systematic review. J Am Acad Dermatol. 2016 Mar. 74 (3):506-12.e11. [Medline]. [Full Text].

  18. Wang YH, Yin HF. [One patient with Kimura's disease and angiolymphoid hyperplasia with eosinophilia also suffers from kidney injury]. Beijing Da Xue Xue Bao. 2008 Aug 18. 40(4):405-7. [Medline].

  19. Dewan P, Francis ND, Lear JT, Bunker CB. Angiolymphoid hyperplasia with eosinophilia affecting the penis. Br J Dermatol. Sept 2008. 159(3):755-7. [Medline].

  20. Huang M, Lloyd WC 3rd, O'Hara M. Angiolymphoid hyperplasia with eosinophilia: an unusual presentation in a child. J AAPOS. Jun 2008. 12(3):302-4. [Medline].

  21. Hamaguchi Y, Fujimoto M, Matsushita Y, Kitamura-Sawada S, Kawano M, Takehara K. IgG4-related skin disease, a mimic of angiolymphoid hyperplasia with eosinophilia. Dermatology. 2011. 223(4):301-5. [Medline].

  22. Lembo S, Balato A, Cirillo T, Balato N. A Long-Term Follow-Up of Angiolymphoid Hyperplasia with Eosinophilia Treated by Corticosteroids: When a Traditional Therapy is Still Up-to-Date. Case Rep Dermatol. 2011 Mar 5. 3(1):64-7. [Medline]. [Full Text].

  23. Horst C, Kapur N. Propranolol: a novel treatment for angiolymphoid hyperplasia with eosinophilia. Clin Exp Dermatol. 2014 Oct. 39(7):810-2. [Medline].

  24. Chacon AH, Mercer J. Successful management of angiolymphoid hyperplasia with eosinophilia in a split-face trial of topical tacrolimus and timolol solution. G Ital Dermatol Venereol. 2014 Jul 11. [Medline].

  25. Isohisa T, Masuda K, Nakai N, Takenaka H, Katoh N. Angiolymphoid hyperplasia with eosinophilia treated successfully with imiquimod. Int J Dermatol. 2012 May 16. [Medline].

  26. Shenefelt PD, Rinker M, Caradonna S. A case of angiolymphoid hyperplasia with eosinophilia treated with intralesional interferon alfa-2a. Arch Dermatol. 2000 Jul. 136(7):837-9. [Medline].

  27. Braun-Falco M, Fischer S, Plötz SG, Ring J. Angiolymphoid hyperplasia with eosinophilia treated with anti-interleukin-5 antibody (mepolizumab). Br J Dermatol. 2004 Nov. 151(5):1103-4. [Medline].

  28. Carlesimo M, Mari E, Tammaro A, Persechino S, Camplone G. Angiolymphoid hyperplasia with eosinophilia treated with isotretinoin. Eur J Dermatol. 2007 Nov-Dec. 17(6):554-5. [Medline].

  29. Abrahamson TG, Davis DA. Angiolymphoid hyperplasia with eosinophilia responsive to pulsed dye laser. J Am Acad Dermatol. 2003 Aug. 49(2 Suppl Case Reports):S195-6. [Medline].

  30. Sotiriou E, Apalla Z, Patsatsi A, Panagiotidou DD, Ioannides D. Angiolymphoid hyperplasia with eosinophilia: good response to photodynamic therapy. Clin Exp Dermatol. 2009 Dec. 34(8):e629-31. [Medline].

  31. Wozniacka A, Omulecki A, Torzecka JD. Cryotherapy in the treatment of angiolymphoid hyperplasia with eosinophilia. Med Sci Monit. 2003 Jan. 9(1):CS1-4. [Medline].

  32. Singh S, Dayal M, Walia R, Arava S, Sharma R, Gupta S. Intralesional radiofrequency ablation for nodular angiolymphoid hyperplasia on forehead: A minimally invasive approach. Indian J Dermatol Venereol Leprol. 2014 Sep-Oct. 80(5):419-21. [Medline].

Previous
Next
 
Angiolymphoid hyperplasia with eosinophilia typically exhibits flesh-color to erythematous nodules in the vicinity of the ear.
Pronounced erythema and nodularity due to angiolymphoid hyperplasia with eosinophilia.
Histologically, angiolymphoid hyperplasia with eosinophilia is marked by thick-walled blood vessels with protuberant endothelium and a prominent inflammatory infiltrate, which typically includes eosinophils.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.